Andre Broussard, MD
Urology · Shreveport, LANPI 1407147291
Payments from drug & device makers
Across 102 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$494
- Pfizer$265
- Teleflex LLC$243
- Coloplast$229
- Baxter Healthcare$150
- Astellas Pharma US Inc$132
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,43892%
- Education$2268%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 19 | $494 |
| Pfizer | 5 | $265 |
| Teleflex LLC | 5 | $243 |
| Coloplast | 8 | $229 |
| Baxter Healthcare | 2 | $150 |
| Astellas Pharma US Inc | 9 | $132 |
| AbbVie(2 entities) | 7 | $113 |
| Edwards Lifesciences | 1 | $102 |
| Boston Scientific | 4 | $97 |
| Merck | 4 | $79 |
| Endo Pharmaceuticals Inc. | 5 | $72 |
| Cook Medical LLC | 4 | $66 |
| Myovant Sciences Inc. | 4 | $64 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Dendreon Pharmaceuticals LLC | 3 | $59 |
| Laborie Medical Technologies Corp. | 1 | $53 |
| Inari Medical, Inc. | 1 | $49 |
| Urogen Pharma, Inc. | 1 | $41 |
| Bayer | 2 | $38 |
| Zyla Life Sciences, Inc. | 2 | $32 |
| Novartis | 2 | $30 |
| Argon Medical Devices, Inc. | 1 | $25 |
| Urovant Sciences Inc | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $21 |
| Telix Pharmaceuticals | 1 | $19 |
| Axonics, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Acacia Pharma Inc | 1 | $16 |
| SRS Medical Systems, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$226
- UroLift System$116
- SAPIEN 3 Ultra RESILIA$102
How this compares
$2,664 in reported general payments places this provider in the 45th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 126 | $98,130 |
| GemtesaVibegron | 158 | $89,560 |
| Tamsulosin Hcl | 1,454 | $16,968 |
| Mirabegron ErMirabegron | 21 | $12,451 |
| Finasteride | 661 | $9,477 |
| ErtapenemErtapenem Sodium | 20 | $8,990 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 345 | $7,771 |
| Solifenacin Succinate | 161 | $4,346 |
| EliquisApixaban | 14 | $3,913 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 38 | $3,073 |
| Silodosin | 45 | $3,033 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 157 | $3,003 |
| Oxybutynin Chloride ErOxybutynin Chloride | 138 | $2,131 |
| Cephalexin | 189 | $1,323 |
| Testosterone Cypionate | 21 | $1,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $132 | $98,130126 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $61 | $89,560158 claims |
| PfizerEliquis | $265 | $3,91314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 199 urology providers in Louisiana.
Other urology in Shreveport
- Ralph HendersonShreveport$4M
- Kevin ClineShreveport$1.3M
- Ashley BakerShreveport$705K
- Jared MossShreveport$365K
- James NobleShreveport$273K
- Jeremy NorwoodShreveport$128K
- Kevin HebertShreveport$54K
- Thomas PalmerShreveport$45K
- Nazih KhaterShreveport$23K
- David PriceShreveport$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.